while receiving methotrexate, azathioprine, or mycophenolate mofetil, we conditionally recommend adding mepolizumab over adding omalizumab. The published evidence on omalizumab, an anti-IgE antibody, in EGPA has been limited. Therefore, even for a patient with high serum IgE levels, mepolizumab is the preferred choice based on evidence from the randomized controlled trial Other considerations Recommendation: For patients with newly diagnosed EGPA receiving leukotriene inhibitors, we